Shinichi Kawai

Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: A multicenter, double‐blind, placebo‐controlled trial

Norihiro Nishimoto, Kazuyuki Yoshizaki, Nobuyuki Miyasaka et al. · Arthritis & Rheumatism · 2004 · 789 citations

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

Jun Hashi­moto, N. Miyasaka, Kazuhiko Yamamoto et al. · Annals of the Rheumatic Diseases · 2007 · 739 citations · Full text

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

Norihiro Nishimoto, Nobuyuki Miyasaka, Kazuhiko Yamamoto et al. · Modern Rheumatology · 2008 · 335 citations · Full text

Immunology, Pharmacotherapy, Dose Mtx +20

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

Naoki Nishimoto, N. Miyasaka, Kazuhiko Yamamoto et al. · Annals of the Rheumatic Diseases · 2008 · 334 citations · Full text

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

Norihiro Nishimoto, Nobuyuki Miyasaka, Kazuhiko Yamamoto et al. · Modern Rheumatology · 2009 · 270 citations · Full text

Immunology, Pharmacotherapy, Dose Mtx +20